Market Overview

With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip

Share:
With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip
Related ALNY
Benzinga's Top Upgrades, Downgrades For November 29, 2018
Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'
Alnylam settles litigation with Silence Therapeutics (Seeking Alpha)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) continued to decline after Pfizer Inc. (NYSE: PFE) reported its transthyretin stabilizer Vyndaqel met primary Phase 3 endpoints Thursday.

However, B Riley FBR considers the ostensible competitor’s victory a positive for Alnylam.

The Rating

Analyst Madhu Kumar maintained a Buy rating on Alnylam with a $200 price target.

The Thesis

Based on absolute clinical data, Alnylam’s transthyretin RNAi pipeline is expected to dominate the TTR amyloidosis space over the next few years, Kumar said in a note.

Pfizer’s success in TTR cardiomyopathy is seen to further derisk Alnylam’s franchise, including its ALN-TTRsc02 asset, which is set to start Phase 3 studies in 2018.

At the same time, Alnylam’s product addresses a different patient set than Vyndaqel does, which means Pfizer’s success does not weigh on Kumar’s bullish Alnylam model, the analyst said. And even where there may be overlap, the analyst said he anticipates victory for Alnylam. 

“We believe anything TTR stabilizers can do, RNAi can do better." 

That advantage is seen in both effectiveness and dosing schedules.

“Taken as a whole, we believe that Alnylam's TTR RNAi franchise could have better efficacy through superior adherence along with increased convenience through reduced treatment burden,” Kumar said. 

B Riley FBR considers Alnylam’s selloff a buying opportunity and ranks the stock as an alpha generator.

Price Action

At the time of publication, shares were trading down 15.73 percent at $100.36. 

Related Links:
The Companies That Led 2017's Biotech Rally
Biotech Winners And Losers From Congress' Latest Funding Bill

Latest Ratings for ALNY

DateFirmActionFromTo
Nov 2018Leerink SwannInitiates Coverage OnMarket Perform
Oct 2018BMO CapitalMaintainsOutperformOutperform
Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: B Riley Madhu KumarAnalyst Color Biotech Price Target Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (ALNY + PFE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
QRVOKeyBancDowngrades0.0
SWKSKeyBancDowngrades0.0
CMAB. Riley FBRDowngrades84.0
COFBairdUpgrades101.0
CORJefferiesDowngrades102.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Trump's Steel And Aluminum Tariffs Could Affect The Robotics And AI Industries

Argus Cites Cardinal Health's Margin Improvements In Upgrade